Payment overview · 2025
General Payments
$24,948.39
134 reported records · 19 companies
Healthcare provider profile · identity verified
Marsha S Smith, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CINCINNATI, OH · NPI 1528003548
Verified facts
What the public records show
CMS Open Payments records show Marsha S Smith, MD received $24,948.39 in general payments during 2025 across 134 reported records.
MDD US Operations, LLC accounted for 45.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gocovri, Ingrezza, Nuplazid, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Qulipta by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Nuplazid by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gocovri by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ingrezza by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $11,389.68 | 45.6% | 61 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $9,859.91 | 39.5% | 33 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,803.06 | 7.2% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,078.05 | 4.3% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $177.88 | 0.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.29 | 0.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $117.90 | 0.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $72.00 | 0.3% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $52.42 | 0.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $45.94 | 0.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.66 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $30.95 | 0.1% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $26.39 | 0.1% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$24.52 | 0.1% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$20.51 | 0.1% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.80 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.78 | 0.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.54 | 0.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $15.11 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Honoraria | $9,560.00 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,064.87 | 9 |
| Food and Beverage | $2,752.31 | 109 |
| Travel and Lodging | $2,632.72 | 10 |
| Consulting Fee | $880.00 | 1 |
| Education | $58.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $10,134.22 | 34 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $9,496.51 | 23 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $6,402.16 | 18 | 2025 |
Source payment records
|
|||||
| Vercise Normalized: vercise |
Device | Boston Scientific Corporation | $1,736.23 | 4 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $1,043.55 | 10 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $363.40 | 10 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $177.88 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $147.29 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $117.90 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $66.83 | 2 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $52.42 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $45.94 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $34.50 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.66 | 1 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $31.60 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gocovri gocovri |
2025 | Gocovri | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 591 | 130 |
| Memantine Hcl | Memantine Hcl | 257 | 76 |
| Primidone | Primidone | 242 | 70 |
| Galantamine Er | Galantamine Hbr | 240 | 67 |
| Gabapentin | Gabapentin | 216 | 52 |
| Lamotrigine | Lamotrigine | 121 | 19 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 107 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 25 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 94 | 20 |
| Memantine Hcl Er | Memantine Hcl | 92 | 21 |
| Levetiracetam | Levetiracetam | 90 | 26 |
| Rasagiline Mesylate | Rasagiline Mesylate | 83 | 19 |
| Donepezil Hcl | Donepezil Hcl | 63 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 20 |
| Clonazepam | Clonazepam | 52 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 49 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 41 | suppressed |
| Amantadine | Amantadine Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Topiramate | Topiramate | 31 | 12 |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 29 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 29 | suppressed |
| Qulipta | Atogepant | 25 | suppressed |
| Gocovri | Amantadine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Ingrezza | Valbenazine Tosylate | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Xcopri | Cenobamate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $24,948.39 · 134 records | MDD US Operations, LLC | AUSTEDO XR, Apokyn, BOTOX, CREXONT, DAXXIFY, Dysport, General - DBS, Gocovri, HYQVIA, INFINITY, INGREZZA, INTELLIS ADAPTIVESTIM, KISUNLA, NUPLAZID, NURTEC ODT, PERCEPT PC BRAINSENSE, QULIPTA, UBRELVY, VALTOCO, VYALEV, Vercise, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gocovri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error